Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
UTHR..$47.33 Oral Treprostinil New Drug Application Accepted by FDA for Review. PDUFA date of Oct. 27th.
http://finance.yahoo.com/news/Oral-Treprostinil-New-Drug-prnews-829289937.html?x=0
GTXI..$3.90 FDA places clinical hold on trials evaluating Capesaris for First & Second Line Treatments of Prostate Cancer. http://bit.ly/wJQ0Vt
EGT: Entertain Gaming Asia. Breaks above 200 mov. Ave.
Thats well worth watching as the 3/08 catalyst earnings and follow CC take place.
PLX..$5.70 Trading strong this morning. March will be a strong month for the company as the call activity is high on this play. http://bit.ly/yKbLm7
SCON..$1.02 Looks like the weak hands are gone. This one wants to move higher. Placement was at $1.05.
Thanks $heff. I am pleased with THLD's performance.
GRVY..$2.98 It broke $3.00 today and hit a new 52wk high at $3.04. Key event is tomorrow & into March as well.
HZNP..$3.26 Looks like a bottom play here. Getting close to the 52wk low here.
THLD..$6.29 Congrats to you on a solid trade. There was a lot of risk with that trade but the reward is excellent with solid appreciation!
SYNM: Breakout on tap from last weeks new & Forbes?
Forbes.
http://www.forbes.com/sites/christopherhelman/2012/02/17/making-cars-carnivores-tyson-venture-turns-animal-fat-into-diesel/?partner=yahoofeed
Last weeks news:
http://finance.yahoo.com/news/Norfolk-Southern-pens-deal-theflyonthewall-4170285501.html?x=0
Note: Rising gasoline prices are helping propel SYNM as well. This one wants to breakout solid above 2.00, imo.
Aoplogy to $heff.....could not find the SYNM thread so strated this one to notify readers.
THLD now at $6 premarket
Cowen comments: THLD - 'TH-302 could easily achieve blckbuster ($1b+) status in pancreatic cancer alone. THLD will get 30-40% of back end value' COWN
SCON DD summary - Placement done, milestones to come.
With recent placement at 1.05 for 4 million they are about ready to start installing their new state of art production facililty
- New low cost technology for Superconducting Wire
- Product samples meeting industry criteria and validated !
- Took possesion of new 90.000 acre state of art facility in January 2012
"The company will set up in a 94,000-square-foot Class A semiconductor manufacturing facility previously occupied by Applied Materials Inc"
Here an overview of their plans.
Note the wire cost with is low also compareing to some of their competitors allready in the market such as AMSC
projected <100$/K-a/m
Wire cost projections
Full update in pdf here: http://www.suptech.com/pdf_presentations/2012invpresentation.pdf
Production partner likely there due to supply restraints in the sector.
Recent and more outlook there than there was before, worth the read:
http://www.statesman.com/business/technology/vacant-clean-rooms-find-new-life-in-superconducting-2039934.html
A) Superconductor Technologies Inc. Takes Possession of Advanced Manufacturing Center of Excellence in Austin, TX
http://finance.yahoo.com/news/Superconductor-Technologies-pz-3998953240.html?x=0
B) Superconductor Technologies Inc. Completes Testing of Conductus(R) 2G HTS Wire with General Cable Superconductor Ltd. for HTS Roebel Cable Applications
Successfully meeting critical current and power handling objectives
http://finance.yahoo.com/news/Superconductor-Technologies-pz-2107429496.html?x=0
C)Superconductor Technologies Inc. Commits Supply of Conductus(R) 2G HTS Wire to Leading Provider of High Power Transmission Cables Demonstration project scheduled to be completed by end of 2012
http://finance.yahoo.com/news/Superconductor-Technologies-pz-1237715445.html?x=0
THLD at $5.68 premarket
SCON NEWS
Superconductor Technologies Inc. to Raise Additional $2.5 Million in Registered Direct Offering
7:50a ET February 21, 2012 (GlobeNewswire) Superconductor Technologies Inc. ("STI" or the "Company") (Nasdaq:SCON) today announced that it has entered into agreements with certain institutional investors for a registered direct placement of approximately $2.5 million of common stock at a price of $1.05 per share. This reflects additional demand for STI's recently announced $4.6 million offering (the "Pending Offering").
This offering is on the same terms and conditions as the Pending Offering. The Company will issue to the investors warrants to purchase up to 1,773,750 shares of common stock. The warrants have an exercise price of $1.35 per share, and are exercisable 6 months after issuance and terminate five years after the date of issuance.
Both offerings are expected to close on or about February 22, 2012, subject to satisfaction of customary closing conditions
Future Link & Business News
http://www.finviz.com/futures.ashx
Eurozone approves new $173B bailout for Greece
(CNN) -- Eurozone finance ministers sealed a deal Tuesday morning for a second bailout for Greece, including €130 billion ($173 billion) in new financing.
http://www.cnn.com/2012/02/20/business/greece-bailout/index.html?hpt=hp_t1
Home Depot’s Earnings, Sales Rise Amid Mild Weather
Home Depot’s quarterly profit beat Wall Street estimates as a warm winter pulled some spring demand forward, boosting sales at the world's largest home improvement chain.
http://www.cnbc.com/id/46433299
Kraft Earnings Miss Expectations, Revenues Rise
Kraft Foods reported quarterly earnings and revenue that missed analysts' expectations on Tuesday, sending its shares lower in premarket trading.
http://www.cnbc.com/id/46433315
Wal-Mart posts solid quarter, US sales up
Wal-Mart Stores Inc won over shoppers during the holiday season, with its Walmart U.S. division posting a 1.5 percent rise in sales at stores open at least a year.
http://www.msnbc.msn.com/id/46462676/ns/business-retail/#.T0OT73lfQr0
Investor 100
Great news for thld. 45 million in the bank over last month from Merck. The drug works and is well tolerated. Low float. Higher dose works better. Those results will be out at upcoming conference.
Leerink Swann cuts Chelsea Therapeutics price target
Feb 21 (Reuters) - Chelsea Therapeutics International Ltd <CHTP.O>:
* Leerink swann cuts Chelsea Therapeutics <CHTP.O> price target to $11 from
$12; rating outperform
Threshold Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results of TH-302 in Patients With Pancreatic <THLD.O>
SOUTH SAN FRANCISCO, CA, Feb 21 (MARKET WIRE) --
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD)
-- Primary endpoint of Progression Free Survival was met with hazard
ratio of 0.61 (p = 0.005).
-- The combination therapy was well tolerated with a safety profile
consistent with prior studies.
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that
its 214 patient randomized controlled Phase 2b clinical trial evaluating
the efficacy and safety of two doses of the investigational agent TH-302
in combination with gemcitabine compared to gemcitabine alone in patients
with first-line advanced pancreatic cancer achieved its primary endpoint,
with a 63% improvement in progression free survival and a safety profile
consistent with previous studies. "With the results of this trial, we are
again very encouraged that TH-302 is conferring benefit to patients with
aggressive and difficult to treat cancers," said Barry Selick, Ph.D.,
Chief Executive Officer of Threshold. "We look forward to its ongoing
development with our partner Merck KGaA in this and other indications."
Clinical Trial Design
Study TH-CR-404 is a multi-center, randomized,
controlled, dose-ranging, Phase 2b crossover clinical trial of TH-302 in
combination with gemcitabine in patients with first line advanced
pancreatic cancer. The primary endpoint of the trial is progression-free
survival. The secondary endpoints are overall response rate, overall
survival, change in CA19-9 as well as various other efficacy and safety
parameters. Tumor response was evaluated at baseline and every eight
weeks using RECIST. Patients for whom monotherapy with gemcitabine is
considered standard therapy were eligible for the trial. Patients were
randomized equally into one of three cohorts: TH-302 at a dose of 240
mg/m2 plus gemcitabine, TH-302 at a dose of 340 mg/m2 plus gemcitabine,
or gemcitabine alone. Patients who successfully completed six cycles of
treatment without evidence of significant treatment-related toxicity or
progressive disease could continue to receive treatment. If a patient
experienced cancer progression on gemcitabine alone, the patient could
cross over into one of the TH-302 plus gemcitabine cohorts. The primary
efficacy analysis was performed based upon 149 investigator-assessed PFS
events and, per protocol, pooled data from the two gemcitabine plus
TH-302 dose groups in comparison to gemcitabine alone.
Results
The
median progression-free survival (PFS) was 5.6 months for patients
treated with gemcitabine in combination with TH-302 at 240 mg/m2 and 340
mg/m2 compared to 3.6 months for patients treated with gemcitabine alone.
The PFS hazard ratio comparing the TH-302 combination to gemcitabine
alone was 0.61 (95% confidence interval: 0.43 - 0.87) which was highly
statistically significant (p = 0.005). The response rate in the
combination arms was 22% compared to 12% in the gemcitabine alone group.
Results also demonstrated greater efficacy in the higher TH-302 dose
group compared to the lower dose group.
The combination was well tolerated with a safety profile that was
consistent with our prior study of this combination regimen. As in that
study, skin and mucosal toxicities related to TH-302 were dose dependent
but not dose limiting. Further detailed information regarding the results
of this trial will be presented at a future major medical conference.
"This study provides the proof of concept demonstration that TH-302
contributes to the efficacy of a known active agent and supports the
rationale for combining TH-302, a hypoxia targeting agent, with other
approved therapies," said Stew Kroll, Senior Vice President of
Biostatistics and Clinical Operations of Threshold.
About Pancreatic Cancer
Pancreatic cancer is a malignant neoplasm of
the pancreas with current treatment options including surgery,
radiotherapy and chemotherapy. Gemcitabine as a single agent or in
combination with other treatments is the most commonly used
chemotherapeutic agent in patients with advanced pancreatic cancer. It is
estimated that approximately 279,000 cases of pancreatic cancer were
diagnosed worldwide in 2008. Pancreatic cancer is the fourth most common
cause of cancer death both in the United States and internationally. The
American Cancer Society estimates that 44,030 people were diagnosed with
pancreatic cancer in the United States in 2011, and approximately 37,660
people died from the disease.
About TH-302
TH-302 is a hypoxia-targeted drug that is thought to be
activated under tumor hypoxic conditions, a hallmark of many cancer
indications. Areas of low oxygen levels (hypoxia) within tissues are
common in many solid tumors due to insufficient blood vessel growth.
Similarly, the bone marrow of patients with hematological malignancies
has also been shown, in some cases, to be extremely hypoxic. TH-302 has
been investigated in over 550 patients in Phase 1/2 clinical trials to
date in a broad spectrum of tumor types, both as a monotherapy and in
combination with chemotherapy treatments and other targeted cancer drugs.
Threshold has several ongoing clinical trials with TH-302 including, but
not limited to, a Phase 3 trial of TH-302 in patients with first-line
advanced soft tissue sarcoma (STS). This randomized, multi-center Phase 3
trial will investigate the use of TH-302 plus doxorubicin compared with
doxorubicin alone. The primary efficacy endpoint is overall survival. The
study is conducted under a Special Protocol Assessment with the U.S. Food
and Drug Administration. It is being run in partnership with the Sarcoma
Alliance for Research through Collaboration (SARC) and aims to enroll 450
patients with metastatic or locally advanced unresectable STS.
In Memorium
The results of this trial are dedicated to the memory of
John G. Curd, MD, Threshold's former Chief Medical Officer who died
unexpectedly on April 20, 2011. John played a key role in the design of
this trial and deserves our recognition and thanks for his efforts on
behalf of all patients living with cancer.
About Threshold Pharmaceuticals
Threshold is a biotechnology company
focused on the discovery and development of drugs targeting Tumor
Hypoxia, the low oxygen condition found in microenvironments of most
solid tumors as well as the bone marrows of some hematologic
malignancies. This approach offers broad potential to treat a variety of
cancers. By selectively targeting tumor cells, we are building a pipeline
of drugs that hold promise to be more effective and less toxic to healthy
tissues than conventional anticancer drugs. For additional information,
please visit our website (www.thresholdpharm.com).
Forward-Looking Statements
Except for statements of historical fact,
the statements in this press release are forward-looking statements,
including statements regarding TH-302's potential uses and benefits and
current and planned clinical trials of TH-302. These statements involve
risks and uncertainties that can cause actual results to differ
materially from those in such forward-looking statements. Potential risks
and uncertainties include, but are not limited to, Threshold's ability to
enroll or complete its anticipated clinical trials, the time and expense
required to conduct such clinical trials and analyze data, whether such
trials confirm results from earlier trials and preclinical studies,
potential side effects associated with TH-302, issues arising in the
regulatory or manufacturing process and the results of such clinical
trials (including product safety issues and efficacy results), and
Threshold's ability to raise additional capital to continue funding its
operations. Further information regarding these and other risks is
included under the heading "Risk Factors" in Threshold's Quarterly Report
on Form 10-Q, which has been filed with the Securities Exchange
Commission on November 3, 2011 and is available from the SEC's website
(www.sec.gov) and on our website (www.thresholdpharm.com) under the
heading "Investors." We undertake no duty to update any forward-looking
statement made in this news release.
CORT bid 4.80 premarket
Jmp raises Corcept Therapeutics <CORT.O> price target from $9 to $11, market
outperform rating
FDA Calendar Week of 2/21-24
$THLD $VVUS $CHTP $CBRX
http://www.biopharmcatalyst.com/fda-calendar/
greek bailout finalized.
http://finance.yahoo.com/news/second-greek-bailout-reach-funding-gap-narrows-015256172.html
BRUSSELS (Reuters) - Euro zone finance ministers approved on Tuesday a second bailout for debt-laden Greece that will resolve Athens' immediate repayment needs but seems unlikely to revive the nation's shattered economy.
After a marathon 12 hours of talks through the night, euro zone officials said ministers had agreed measures to cut Greece's debt to around 121 percent of gross domestic product by 2020, close to their original target of 120, after negotiators for private bondholders offered to accept a bigger loss to help plug the funding gap.
Agreement on a 130-billion-euro rescue package with strict conditions attached will help draw a line under months of uncertainty that has shaken the currency bloc, and avert an imminent bankruptcy.
"The financial volume (of the Greek package) is 130 billion euros and debt-to-GDP (will be) 121 percent. Now it's down to work on the statement," one official involved in the negotiations told Reuters. Another confirmed the two figures.
The euro jumped almost half a cent, reversing earlier losses, after Reuters reported a deal had been struck.
A report prepared for ministers by EU, European Central Bank and IMF experts, obtained exclusively by Reuters, said Greece would need extra relief to cut its debts near to the official debt target 2020 given the ever-worsening state of its economy.
If Athens did not follow through on economic reforms and savings, its debt could hit 160 percent by that date.
"Given the risks, the Greek program may thus remain accident-prone, with questions about sustainability hanging over it," the 9-page confidential report said, highlighting the fact that Greece's problems are far from over.
The accord will enable Greece to launch a bond swap with private investors to help reduce and restructure Athens' vast debts, put it on a more stable financial footing and keep it inside the 17-country euro zone.
Greece will have around 100 billion euros of debt written off as banks and insurers will swap bonds they hold for longer-dated securities that pay a lower coupon.
Private sector holders of Greek debt are expected to take losses of 53.5 percent or more on the nominal value of their bonds as part of a debt exchange that will reduce Greece's debts by around 100 billion euros.
Previously they had agreed to take a 50 percent nominal writedown, which equated to around a 70 percent loss on the net present value of the bonds.
The debt sustainability report delivered to ministers last week showed that without further measures Greek debt would only fall to 129 percent by 2020.
The IMF had said if the ratio was not cut to near 120 percent, it may not have been able to help finance the bailout.
Diplomats and economists say the deal may only delay a deeper default by a few months. A turnaround could take as much as a decade, a prospect that brought thousands of Greeks onto the streets to protest against austerity measures on Sunday.
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
Euro zone crisis in graphics http://r.reuters.com/hyb65p
^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^
DOUBTS OVER COMMITMENT
Skeptics question whether a new Greek government will stick to the deeply unpopular program after elections due in April, and believe Athens could again fall behind in implementation, prompting exasperated lenders to pull the plug once the euro zone has stronger financial firewalls in place.
While there are doubts in Germany and other countries that Greece will be able to meet its commitments, including implementing 3.3 billion euros of spending cuts and tax increases, the threat of contagion from a chaotic Greek default always made a deal more likely than not, no matter how tortuous the negotiations.
Greek Prime Minister Lucas Papademos, International Monetary Fund Managing Director Christine Lagarde and ECB President Mario Draghi all attended the Brussels talks in a sign they were likely to be decisive.
The private creditor bond exchange is expected to launch on March 8 and complete three days later, Athens said on Saturday. That means a 14.5-billion-euro bond repayment due on March 20 would be restructured, allowing Greece to avoid default.
The vast majority of the funds in the 130-billion-euro program will be used to finance the bond swap and ensure Greece's banking system remains stable: 30 billion euros will go to "sweeteners" to get the private sector to sign up to the swap, 23 billion will go to recapitalize Greek banks.
A further 35 billion will allow Greece to finance the buying back of the bonds, and 5.7 billion will go to paying off the interest accrued on the bonds being traded in. Next to nothing will go directly to help the Greek economy.
Those numbers could change in the final analysis given the scramble to meet the overall objective of reducing Greece's debts from 160 percent of GDP to around 120 by 2020.
Earlier, euro zone sources said national central banks in the currency bloc could restructure Greek bonds held in their investment portfolios in the same way as private investors, cutting Athens' debt by 3.5 percentage points.
If the ECB were to forego profits on its Greek holdings, that would raise another 5.5 percentage points of GDP, the report showed.
The deal will provide immediate relief to Athens and financial markets but no one is pretending it will end Greece's problems. Figures last week showed its economy shrank 7 percent year-on-year in the last quarter of 2011, much more than expected, with further cuts likely to make matters worse.
The troika of European Commission, ECB and IMF, responsible for monitoring Greece's reform progress, carries out quarterly reviews and could decide Athens is not meeting its commitments at any one of them.
BUT, will we revisit this again?
The first details of the Greek bond deal are leaking out via Reuters, and we now learn the reason for the Greek bond sell off in recent days:
•UNDER GREEK DEBT SWAP, PRIVATE SECTOR WILL GET 3% COUPON ON BONDS FROM 2012-20, 3.75% COUPON FROM 2021 ONWARDS [2021... LOL]
•PRIVATE SECTOR WILL ALSO GET A GDP-LINKED ADDITIONAL PAYMENT, CAPPED AT 1 PCT OF THE OUTSTANDING AMOUNT OF NEW BONDS [If it appears that nobody gives a rat's ass about this bullet point, it's because it's true]
•GREEK BANK RECAPITALISATION NEEDS MAY NOW BE AS MUCH AS 50 BLN EUROS-DEBT SUSTAINABILITY ANALYSIS
Which in turn explains the sell off in pre-petition Greek junior triple subordinated bonds (i.e., those held by private unconnected investors, which are subordinated to the Troika's bailout loans, to the ECB's SMP purchases, to the Public Sector bonds and to UK-law bonds in that order). With the EFSF Bill "sweetener" amounting to about 15 cents (and likely less), the fact that bondholders will receive a 3% cash coupon, a cash on cash return based on Greek bonds of 2015 trading at just 20.7 cents on the euro, indicates that investors are expecting to collect 1 cash coupon payment, and at absolute best 2, before redefault, as buying a 2015 bond now at 20.7 of par, yields a full cash return of 21 (15+3+3), thus the third coupon payment is assured not to come. And since there is a substantial upside risk premium kicker to bond buyers, in reality the investing market is saying that Greece will last at best about a year following the debt exchange (if it ever even happens) before the country redefaults.
Oh, and by the way, the fact that creditors just got even more bent over, just assures that Greece can kiss the 75% threshold for PSI acceptance goodbye. Hello CACs, and CDS trigger.
Some more just out of Reuters:
Greece will need additional relief if it is to cut its debts to 120 percent of GDP by 2020 and if it doesn't follow through on structural reforms and other measures, its debt could hit 160 percent by 2020, a debt sustainability report by the IMF, European Central Bank and European Commission shows.
The baseline scenario is that Greece will cut its debt to 129 percent of GDP in 2020 from 160 percent now, well above the targeted 120 percent, the confidential, 9-page analysis prepared for euro zone finance ministers showed.
"The results point to a need for additional debt relief from the official or private sectors to bring the debt trajectory down," said the report, dated Feb. 15 and obtained by Reuters.
The report forms the basis of discussions of euro zone ministers on the conditions under which Greece is to get further financial help from the euro zone and the IMF.
"There is a fundamental tension between the program objectives of reducing debt and improving competitiveness, in that the internal devaluation needed to restore Greece competitiveness will inevitably lead to a higher debt to GDP ratio in the near term," the report said.
"In this context, a scenario of particular concern involves internal devaluation through deeper recession (due to continued delays with structural reforms and with fiscal policy and privatisation implementation)," it said.
"This would result in a much higher debt trajectory, leaving debt as high as 160 percent of GDP in 2020. Given the risks, the Greek program may thus remain accident-prone, with questions about sustainability hanging over it," it said.
It appears nothing has been resolved. YET AGAIN
QCOR agreed QCOR will be a great $$$ maker this week imo easily s/b $38 to $40 after earnings blowout....
OT- This is a great story about how this technology was able to help these kids.
Genome Proving Cure for Ailing Twins Paves Breakthrough to Doctor’s Office
http://www.bloomberg.com/news/2012-01-30/genome-proving-cure-for-ailing-twins-paves-breakthrough-to-doctor-s-office.html
I took advantage of changing from a traditional 401k fund-based account to a 401k self-directed brokerage account. I will caveat that by noting that I'm more conservative with that account than with my non-retirement trading account. I do hold some duplicate tickers in both accounts, but the 401k involves more diversified and smaller positions.
PLX..$5.61 Notable Call Options Activity in Protalix BioTherapeutics.
http://bit.ly/yKbLm7
Hey Sheff,
Do you mind sharing what broker you use? I'm not thrilled with the service I'm getting when I place orders with Schwab. Thanks.
OT: Cashing out my 401(k) early was a costly mistake. http://yhoo.it/ybwARa
Good article from a first person perspective.
QCOR:$QCOR to rise on blowout earnings Wed
Originally posted by RRU2S
QCOR’s upcoming earnings report is Wednesday, Feb. 22, and will show their TTM EPS saw a 40.5% increase (from 0.83 to 1.17). This increase is pretty much fact, as a 2/16/12 8K filing presented a pre-release of information showing net income (before taxes) will be in the range of $41M to $43M. Based on that data and the expected tax rate, the quarter ending 12/31/11 should yield an EPS of 0.44 (= 42/33.7 x 0.35).
The 40.5% TTM EPS change represents a big chart play, especially after a StreetSweeper report back in January allowed shorts to drop QCOR’s PPS by 19%. However, the rather weak StreetSweeper report was effectively refuted in a rebuttal issued by QCOR. Note QCOR earnings are expected to rise throughout 2012, which is attributable to effective marketing of their approved drug for several conditions. QCOR has lots of cash, and should do well in 2012.
Backup info:
Period___________________12/10____3/11____6/11____9/11_____12/11
Diluted EPS________________0.10____0.17____0.21_____0.35_____0.44--(projected)
Net.Inc.B4_tax______________10.9___16.6____20.4_____33.7______42--(projected)
Net.Inc.after.Tx_____________6.42___11.2_____13.87____22.85____28.48--(projected)
ratio income B4/after tax____________________1.4704___1.4747___1.4747--(projected)
Sharecount________________65.39___65.37___65.46____66.02____66.02--(projected)
N.I./(EPS x Sh.Ct)___________0.9813__1.0099__1.0093___0.9889___0.9889--(projected)
-----------------------------------------------------------------
QCOR:$QCOR huge institutional ownership, small retail float
92.9% institutional ownership (59M out of 64M sharecount):
http://www.nasdaq.com/symbol/qcor/institutional-holdings
-----------------------------------------------------------------
QCOR:$QCOR 54% upside 12 mo. PPS target
54% upside (12 month analyst price target consensus $51.50 vs. current $33.56)
http://www.nasdaq.com/symbol/qcor/analyst-research
----------------------------------------------------------------
QCOR:$QCOR Strong Buy: 7/7 Analysts
Rated strong buy from 7 out of 7 analysts:
http://www.nasdaq.com/symbol/qcor/recommendations
-----------------------------------------------------------------
QCOR:$QCOR 17% of float Short Interest
Latest Short Interest: 10.6M (17% of float or 233% of retail interest (non-institutional ownership)
http://www.nasdaq.com/symbol/qcor/short-interest
------------------------------------------------------------------
QCOR:$QCOR $214M cash, buyback record, debt free
Cash flow positive ($214M cash/short term investments) and debt free:
Source: 8K filed 2/16/12
15M share buybacks completed, 4.3M additional share repurchases authorized
Source: 8K filed 2/16/12
------------------------------------------------------------------
QCOR:$QCOR effective rebuttal to StreetSweeper report
Link to QCOR’s professional and effective rebuttal of a weak StreetSweeper short-selling report:
http://www.streetinsider.com/Corporate+News/Questcor+%28QCOR%29+Issues+Response+to+StreetSweeper+ReportAllegations/7084149.html
Soon after this rebuttal was issued, StreetSweeper's short position decreased substantially; evidently they covered when they saw the preliminary news of QCOR's upcoming blowout earnings report. However, not all shorts have covered, based on NASDAQ latest daily short interest.
------------------------------------------------------------------
Investor 100
$QCOR effective rebuttal to StreetSweeper report
Link to QCOR’s professional and effective rebuttal of a weak StreetSweeper short-selling report:
http://www.streetinsider.com/Corporate+News/Questcor+%28QCOR%29+Issues+Response+to+StreetSweeper+ReportAllegations/7084149.html
Soon after this rebuttal was issued, StreetSweeper's short position decreased substantially; evidently they covered when they saw the preliminary news of QCOR's upcoming blowout earnings report. However, not all shorts have covered, based on NASDAQ latest daily short interest.
If you look at the AMRN chart it has been a traders dream. these swings like on Firday have been going on for over the past year. the trend off its low has been up
http://finance.yahoo.com/echarts?s=AMRN+Interactive#chart1:symbol=amrn;range=1y;indicator=volume;charttype=line;crosshair=on;ohlcvalues=0;logscale=on;source=undefined
CORT annotated chart as posted wednedsay 15th , link back for it
GRVY: Very interesting preview. LINK.
Please read the entire preview/review from Saturday.
Of note is the requirement that players form groups, some large, some small, in order to do battle. A live chat feature is embeded in the game making it a state of the art social network platform.
My understanding from contact with Gravity is that each country, as it lights up, will be linked on the same chat platform, providing a true global forum allowing players around the world to communicate in real time.
http://news.mmosite.com/content/q/2012-02-18/ro2_open_beta_preview_khara_system_and_more_1.shtml
good poster name buddy, i just learned my lesson with CORT.
Sheff Station @ Stockcharts
There has been a surge in price appreciation with many of the selections this week along with new entry points..take a look and thanks to all that contribute at the Sheff Station!
AFFY:$10.55
CORT:$3.03
Corcept Therapeutics drug Korlym gets FDA approval
ECYT:$3.77
http://www.nasdaq.com/symbol/ecyt/institutional-holdings/new
GNOM:$3.92
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=71745253
GRVY:$2.89
PLX..$5.61 Traded really well today & it looked like the start of a rebound after the offering. I bought shares at $5.50 as I thought that was the price an uptrend was confirmed (link post). It should trade nicely into their PDUFA date of May 1st.
AMRN..$8.57 Crazy downward spiral in the latter part of the day. Exited position at $9.00 from $8.65 entry. Had discussed earlier how patience was rewarded when it was way over $9.00. Tried to lock in profit earlier at $9.20 but missed the opportunity. It had hit $9.38 for the high of the day. Not sure why the downturn, but it was strong. I will look to re-enter at a later time. Someone was eager to get out today as there was a lot of selling in the last hr of the day. I wondered if there was negative news out on the patent issue, but I have not heard or seen anything.
Sheff - Been a while so Hi. Cort resumed trading AH and now is up about 65% for the day. Only 5% of the float was listed as short (Finviz) but likely some are covering in AH after the approval.
The target Finviz has is $7, but then someone had said it could go 3x recent lows. If either is accurate it should go up from here by mid week I would assume.
Sheff what are your thoughts? The drug is supposed to be worth about 516M by 2016
TIA
Trade
OT: Thank you! We have great traders on this thread. We are all here to help each other & assist free of charge. You won't find $600 subscription fees to get good info here. If you or anyone else is paying a subscription service for biotech information I will personally smack you between the eyes:) It is not needed. Do your homework and DD and your trades will work out. There are no "GURUS" here. We are all here to help each other. Continued success!
CORT UP 27.06% AH TRADING as of 4:12
Suprised a few and congrats for those who held!
look forward to the next Conference call, to discuss prospectus.
gl
Philip Frost is an extremely successful individual. Now if you have some time and really do some digging you will be amazed at just how he is affiliated and invested in so many other companies. OPK seems to be a no brainer as he continues to buy stock even at these levels. This is basically the same thing he did with IVAX which he ended up selling to TEVA who ironically he is on the board of.
Ok thanks,
.
.
what info I read, I almost feel like I'm watching the analogy of the Yankees buying a World Series outside the fact of the CEO if that makes sense.
OPK is all about the management and you will not get a better CEO
cort: congrates to those who were long , i was short, lesson learned, bad call from my side.
First posting here. In GRVY 2.60 earlier this week. SCON .95 Today. Both making some $
I found that there was some great DD on this board. Congrats to $heff for the excellent work done here and to all the investors who take the time to identify great opportunities and post them for all to benefit.
Tradeberny
Follow Me on Twitter: http://twitter.com/SheffStation/
New Economy Portfolio: Larger Cap stocks for slower but more consistent gains. Some Longer-Term Plays (30-60 days maybe longer)
Beginner Portfolio: Scalp Plays & Low Float Biotechs for potential explosive Growth. Quick Turnover 1-30 days (smaller balance want aggressive growth)
Position Size: STARTER: (1-5% Portfolio Balance) SOLID: (6-10% Portfolio Balance) FULL : (11-20% Portfolio Balance)
NEW ECONOMY PORTFOLIO | Sell Date | Ticker | Buy PPS | Sell PPS | Gain/Loss | Notes | % + or - | ||
| |||||||||
|
| ||||||||
|
| | |||||||
|
| ||||||||
|
| | |||||||
|
| | |||||||
| |||||||||
| | ||||||||
Beginner Portfolio Economy | | ||||||||
BUY DATE | SELL DATE | TICKER | BUY PPS | SELL PPS | Gain/Loss | NOTES | % + or - | ||
|
| ||||||||
| | ||||||||
| |||||||||
| |||||||||
| |||||||||
$HEFF LEARNING STATION-LINKS
REAL-TIME Futures Quotes: http://www.sgxniftydowfutureslive.com/index_files/DOWFUTURES.htm …
JANNEY HEALTHCARE NEWSLETTER-http://www.janney.com/institutions--corporations/investment-banking/industry-groups/healthcare/life-sciences-newsletter
Traders: Develop Your Mental Edge by Dr. Andrew Menaker http://j.mp/1phyFIY
Jesse Livermore-Reminiscences Of A Stock Operator-Great Book http://bit.ly/VOObyM
LIFE SCIENCES MARKET : http://www.thelifesciencesreport.com CHMP Decisions Here: http://t.co/7jjqFyn3tx
E-booklet onTrend Determination: A quick accurate and effective methodology using RSI. http://bit.ly/17PmHZ8
The Original Turtle Trading Rules: Rules of the “Turtle Traders;” one of the greatest trading experiments conducted.
http://bit.ly/17jXegf
FAVORITE QUOTES:
"Compounding interest is the eighth wonder of the world. He who understands it, earns it..he who doesn't.. pays it." - Albert Einstein
"Your actions speak so loud I can't hear your words! When that happens, you have found a certain level of success others haven't." Sheff
"IF YOU ARE NOT TAKING YOUR PROFITS, SOMEBODY ELSE IS !" SHEFF
A good name is more desirable than great wealth. Respect is better than silver or gold. -Proverbs 22:1
Don't brag about yourself let others praise you. -Proverbs 27:2
Do not brag about tomorrow, because you do not know what another day may bring. -Proverbs 27:1
One man pretends to be rich, yet has nothing. Another pretends to be poor, yet has great wealth. Proverbs 13:7
You can easily judge the character of a man by how he treats those who can do nothing for him. -James D. Miles
Favorite Sheff Quote: "You can't let praise or criticism get to you. It's a weakness to get caught up in either one." -John Wooden
Favorite Sheff Quote: Talent is God given. Be humble. Fame is man-given. Be grateful. Conceit is self-given. Be careful.
A Trading Plan = Study. A watch-list. Position Sizing. Entries. Exits. Records. Discipline. h/t @sjburns
5 Things I didn't come on twitter to do: Convince anyone of anything , Argue Defend myself Battle Trolls Waste time @sjosephburns
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |